Stefania Napolitano , Davide Ciardiello , Eleonora Cioli , Erika Martinelli , Teresa Troiani , Maria Giulia Zampino , Nicola Fazio , Ferdinando De Vita , Fortunato Ciardiello , Giulia Martini
{"title":"BRAFV600E mutant metastatic colorectal cancer: Current advances in personalized treatment and future perspectives","authors":"Stefania Napolitano , Davide Ciardiello , Eleonora Cioli , Erika Martinelli , Teresa Troiani , Maria Giulia Zampino , Nicola Fazio , Ferdinando De Vita , Fortunato Ciardiello , Giulia Martini","doi":"10.1016/j.ctrv.2025.102905","DOIUrl":null,"url":null,"abstract":"<div><div>Detection of the <em>BRAF V600E</em> mutation has important genetic, prognostic, and therapeutic implications for patients with metastatic colorectal cancer (mCRC), identifying a subgroup of patients who derive modest benefit from standard treatments and have extremely poor prognosis.</div><div>The evolution of molecular profiling and the implementation of next generation sequencing in the evaluation of a patient with <em>BRAF</em>-mutated mCRC has currently led to the discovery of actionable alterations. Targeting multiple pathways of resistance in <em>BRAF</em>-mutated mCRC may be the most efficacious route. Then, over a short period of time, the treatment landscape <em>BRAF-</em>mutated mCRC patients has shifted dramatically. Finally, novel treatment strategies are available.</div><div>This review will discuss on currently approved treatments for <em>BRAF V600E</em> mutated mCRC and will try and portray the changing landscape in this setting in the era of targeted molecular therapy.</div></div>","PeriodicalId":9537,"journal":{"name":"Cancer treatment reviews","volume":"134 ","pages":"Article 102905"},"PeriodicalIF":10.5000,"publicationDate":"2025-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer treatment reviews","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0305737225000271","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Detection of the BRAF V600E mutation has important genetic, prognostic, and therapeutic implications for patients with metastatic colorectal cancer (mCRC), identifying a subgroup of patients who derive modest benefit from standard treatments and have extremely poor prognosis.
The evolution of molecular profiling and the implementation of next generation sequencing in the evaluation of a patient with BRAF-mutated mCRC has currently led to the discovery of actionable alterations. Targeting multiple pathways of resistance in BRAF-mutated mCRC may be the most efficacious route. Then, over a short period of time, the treatment landscape BRAF-mutated mCRC patients has shifted dramatically. Finally, novel treatment strategies are available.
This review will discuss on currently approved treatments for BRAF V600E mutated mCRC and will try and portray the changing landscape in this setting in the era of targeted molecular therapy.
期刊介绍：
Cancer Treatment Reviews
Journal Overview:
International journal focused on developments in cancer treatment research
Publishes state-of-the-art, authoritative reviews to keep clinicians and researchers informed
Regular Sections in Each Issue:
Comments on Controversy
Tumor Reviews
Anti-tumor Treatments
New Drugs
Complications of Treatment
General and Supportive Care
Laboratory/Clinic Interface
Submission and Editorial System:
Online submission and editorial system for Cancer Treatment Reviews
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
